Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Having successfully completed parent study B7601003.~* Clinical diagnosis of Parkinson's disease.~* Able to refrain from any Parkinson's disease medication not permitted by the protocol.~Exclusion Criteria:~* Female of childbearing potential.~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 87 Years
- Healthy Volunteers: f

Study Arms:
- 1 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 1 mg QD to 15 mg QD PF-06649751
- 3 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 3 mg QD to 15 mg QD PF-06649751
- 7 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 7 mg QD to 15 mg QD PF-06649751
- 15 mg QD PF-06649751 (Type: EXPERIMENTAL): 15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
- 1 mg to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
- 3 mg QD to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
- 7 mg QD to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): 7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
- 15 mg to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): 15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751

Based on this trial design, predict the completion outcome and termination type (if applicable).